|本期目录/Table of Contents|

[1]李爱梅,冯雪凤,孙一文,等.120例重症甲状腺功能亢进患者131碘化钠治疗效果的随访观察[J].医学研究与战创伤救治(原医学研究生学报),2015,17(03):236-238.[doi:10.3969/j.issn.1672-271X.2015.03.004]
 LI Ai-mei,FENG Xue-feng,SUN Yi-wen,et al.Follow-up of 120 patients with severe Graves’ disease after radioiodine therapy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(03):236-238.[doi:10.3969/j.issn.1672-271X.2015.03.004]
点击复制

120例重症甲状腺功能亢进患者131碘化钠治疗效果的随访观察()

《医学研究与战创伤救治》(原医学研究生学报)[ISSN:1672-271X/CN:32-1713/R]

卷:
第17卷
期数:
2015年03期
页码:
236-238
栏目:
出版日期:
2015-05-20

文章信息/Info

Title:
Follow-up of 120 patients with severe Graves’ disease after radioiodine therapy
作者:
李爱梅冯雪凤孙一文陈德柱郭万华
210009 江苏南京,南京大学医学院附属南京鼓楼医院核医学科
Author(s):
LI Ai-mei FENG Xue-feng SUN Yi-wen CHEN De-zhu GUO Wan-hua.
Nuclear Medicine Department of Nanjing Drum Tower Hospital, A Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, China
关键词:
重症甲状腺功能亢进131I放射治疗随访
Keywords:
severe Graves’ disease 131I radioiodine therapy follow up
分类号:
R581.1
DOI:
10.3969/j.issn.1672-271X.2015.03.004
文献标志码:
A
摘要:
目的 回顾性分析重症甲状腺功能亢进(甲亢)患者131碘化钠(131I)治疗后的随访结果与剂量的关系。方法 选择2005年1月-2014年1月就诊于南京大学医学院附属鼓楼医院核医学科并接受131I内照射治疗且随访时间大于1年的120例重症甲亢患者。入选标准:促甲状腺素(thyroid stimulating hormone,TSH)<0.005 mIU/L,游离三碘甲状腺原氨酸(free triiodothyronine,FT3)>50 pmol/L,游离甲状腺素(free thyroxine,FT4)>100 pmol/L。结果 在半固定剂量的前提下个体化剂量治疗1次或多次后,120例中完全缓解率为12.50%(15/120),1年以上甲减发生率为83.33%(100/120),以优甲乐25~125 μg/d替代治疗,患者复发率4.17%(5/120)。结论 应在可能的范围内调整131I到最适剂量减少甲减发生率,提高完全缓解率,提高患者满意度。
Abstract:
Objective To investigate the incidence of hypothyroidism and factors affecting the treatment effect of radioiodine therapy for severe Graves’ disease (GD) more than 1 years after treatment.Methods 120 cases of GD in Nanjing drum tower hospital of Nanjing university medical school from January 2005 to January 2014 were retrospectively studied. Data including blood tests TSH<0.005 mIU/L, FT3>50 pmol/L and FT4>100 pmol/L, symptoms, signs, effective radioactive iodine uptake (RAIU), radioiodine doses and hypothyroidism incidences were collected.Hypothyroidism was also recorded. Student t-test was analyzed.Results The hypothyroidism incidence was 83.33%(100/120). Complete remission incidence was 12.50% (15/120).Recurrence incidence was 4.17% (5/120).Conclusion In order to decrease hypothyroidism incidence and enhance happiness, Optimum delivered 131I dose will be suggested to GD patients.

参考文献/References:

[1]黄 钢.科学应用指南,合理首选甲状腺功能亢进131I治疗[J].中华核医学与分子影像杂志,2013,33(2):81-82.
[2]王加林,王 猛,杨文娟,等.131I治疗甲状腺功能亢进症合并2型糖尿病101例[J].东南国防医药,2011,13(2):109-112.
[3]中华医学会核医学分会.131I治疗格雷夫斯甲亢指南(2013版)[J].中华核医学与分子影像杂志,2013,33(2):83-95.
[4]Ross DS.Radioiodine therapy for hyperthyroidism[J].N Engl J Med,2011,364(6):542-550.
[5]Krohn T, Hnscheid H, Müller B,et al.Maximum dose rate is a determinant of hypothyroidism after 131I therapy of Graves’ disease but the total thyroid absorbed dose is not[J].J Clin Endocrinol Metab,2014,99(11):4109-4115.
[6]Moura-Neto A,Mosci C,Santos AO,et al.Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves’ disease[J].Clin Nucl Med,2012,37(6):550-554.
[7]Lewis A,Atkinson B,Bell P,et al.Outcome of 131I therapy in hyperthyroidism using a 550MBq fixed dose regimen[J].Ulster Med J,2013,82(2):85-88.
[8]蒋宁一.对《131I治疗格雷夫斯甲亢指南(2013版)》有关问题的解答[J].中华核医学与分子影像杂志,2014,34(1):3-4.
[9]Enes Romero P,Martín-Frías M,de Jesús M,et al.Efficacy of treatment with I(131) in paediatric Graves disease[J].An Pediatr (Barc),2014,80(1):16-20.
[10]Ostroumova E,Rozhko A,Hatch M,et al.Measures of thyroid function among Belarusian children and adolescents exposed to iodine-131 from the accident at the Chernobyl nuclear plant[J].Environ Health Perspect,2013,121(7):865-871.
[11]Cui S,Jiao L,Tan J,et al.Estimating radiation absorbed dose of individuals nearby 131I-treated hyperthyroid patients[J].Health Phys,2014,106(3):365-369.
[12]张海三,张红星,刘保平.Graves病患者131I治疗后疾病影响程度与生活质量变化[J].中华行为医学与脑医学杂志,2014,23(10):904-908.
[13]缪汉韬,陈敬芳,尹 宁,等.2012年某院健康体检人员甲状腺结节检出情况分析[J].东南国防医药,2014,14(1):86-88.

相似文献/References:

备注/Memo

备注/Memo:
国家自然基金面上项目(81171363)
更新日期/Last Update: 2015-05-20